Literature DB >> 22494415

IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.

H-Y Chao1, Z-X Jia, T Chen, X-Z Lu, L Cen, R Xiao, N-K Jiang, J-H Ying, M Zhou, R Zhang.   

Abstract

INTRODUCTION: Gene mutations play an important role in acute myeloid leukemia (AML) pathogenesis. Several genes have been identified in AML, such as FLT3, KIT, NPM1, and JAK2. This study investigated the frequency of novel mutations in IDH1 (amino acid R132) and IDH2 (R140 and R172) and analyzed their impact on disease biology and interaction with other mutations in Chinese patients with de novo AML.
METHODS: A total of 195 patients were screened for mutations in the IDH1, IDH2, JAK2 V617F, NPM1, FLT3, and KIT genes, using polymerase chain reaction (PCR)-based and direct sequencing assays.
RESULTS: IDH mutations occurred at a considerable frequency of 15.89% in Chinese AML cases; IDH2 R140Q was the most frequent genetic alteration and was associated with older age, normal karyotype, and French-American-British classification M2 at diagnosis. There was a strong association of IDH2 mutation with NPM1 mutations and a trend with FLT3-internal-tandem duplication.
CONCLUSION: IDH mutations may be a novel genetic marker in cytogenetically normal AML and may cooperate in leukemogenesis.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22494415     DOI: 10.1111/j.1751-553X.2012.01422.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   3.450


  4 in total

1.  Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.

Authors:  Sang Hyuk Park; Jae-Cheol Choi; Shine Young Kim; Jongyoun Yi; Seung Hwan Oh; In-Suk Kim; Hyung-Hoi Kim; Chulhun Ludgerus Chang; Eun Yup Lee; Moo-Kon Song; Ho-Jin Shin; Joo Seop Chung
Journal:  Biomed Res Int       Date:  2015-01-11       Impact factor: 3.411

Review 2.  Next generation sequencing of acute myeloid leukemia: influencing prognosis.

Authors:  Asad Muhammad Ilyas; Sultan Ahmad; Muhammad Faheem; Muhammad Imran Naseer; Taha A Kumosani; Muhammad Hussain Al-Qahtani; Mamdooh Gari; Farid Ahmed
Journal:  BMC Genomics       Date:  2015-01-15       Impact factor: 3.969

3.  Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.

Authors:  Rui Huang; Xiwen Liao; Jing Li; Jiemin Wei; Xiayun Su; Xiaoxuan Lai; Beicai Liu; Fangxiao Zhu; Yumei Huang; Qiaochuan Li
Journal:  Oncol Rep       Date:  2019-03-18       Impact factor: 4.136

4.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

Authors:  Courtney D DiNardo; Kathleen J Propert; Alison W Loren; Elisabeth Paietta; Zhuoxin Sun; Ross L Levine; Kimberly S Straley; Katharine Yen; Jay P Patel; Samuel Agresta; Omar Abdel-Wahab; Alexander E Perl; Mark R Litzow; Jacob M Rowe; Hillard M Lazarus; Hugo F Fernandez; David J Margolis; Martin S Tallman; Selina M Luger; Martin Carroll
Journal:  Blood       Date:  2013-05-02       Impact factor: 25.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.